SAB Biotherapeutics, Inc. (SABSW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Sioux Falls, SD, アメリカ. 現CEOは Samuel J. Reich.
SABSW を有する IPO日 2021-10-25, 63 名の正社員, に上場 NASDAQ Global Market, 時価総額 $238.95K.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
